PRIMA-1 (p53 reactivation and induction
Introduction
Under physiologic conditions in normal cells, p53 protein is expressed at low levels and has a short half-life due to rapid turnover mediated by ubiquitination and proteolysis (1) . The p53 protein becomes stabilized and activated in response to a number of stimuli, including exposure of cells to DNA-damaging agents and oncogene activation. The activation of p53 allows it to carry out its function as a tumor suppressor through cell cycle arrest, apoptosis, DNA repair, differentiation, and antiangiogenesis (2 -7). At least 50% of human tumors contain mutations or deletions of p53 (8) . The fact that the specific DNA-binding function of p53 is disrupted in most tumors with a p53 mutation indicates that this function is critical for p53-mediated tumor suppression. p53-dependent cell death is a major pathway for the efficacy of cancer chemotherapy, and tumors carrying mutant p53 are often more resistant to chemotherapy than tumors with wild-type (WT) p53 (9) . The wide range of the biological effects of p53 can be explained by its activation of expression of a number of target genes (>60), including p21; growth arrest; and DNA damage-inducible (GADD) family proteins, 14-3-3j, MDM2, cyclins, transforming growth factor-h, Bax, and Fas/APO1 (1). p21 is not only a cyclin-dependent kinase inhibitor but also acts as a direct participant in regulating genes involved in growth arrest, senescence, and aging, thus providing an additional layer of control over the cell cycle (10) . Induction of p21 caused a number of different cell lines to arrest in both G 1 and G 2 (11) . GADD45 and 14-3-3j are transcriptional targets of WT p53 and act as mediators of p53-dependent G 2 arrest. GADD45 is also regulated in a p53-independent manner (12) .
The mitogen-activated protein kinase (MAPK) family comprises c-Jun-NH 2 -kinase (JNK), p38 MAPK, and several extracellular signal-regulated kinases (ERK). This signal transduction pathway has been implicated in many physiologic processes, including growth, differentiation, survival, and cell death through a p53-independent mechanism (13) . JNK and p38 MAPK signaling pathways are also activated by various and overlapping stimuli, such as heat shock, radiation, growth factors, and some chemotherapy drugs (14 -16) . In JNK family proteins, the 10 isoforms are encoded by three genes-JNK1, JNK2, and JNK3 (17) . JNK1 protein kinase activation requires phosphorylation on Thr 183 and Tyr 185 (18) . Expression of the dominant-negative JNK (DN-JNK), which is the mutant JNK1 isoform where the sites of activating Thr 183 and Tyr 185 phosphorylation are replaced with Ala and Phe, respectively, markedly suppressed the ability of paclitaxel to induce apoptosis (19) .
The p53 mutant Ala 143 is a human temperature-sensitive mutant p53 with two conformational states. At 32.5jC, it possesses strong DNA-binding ability and functions like WT p53; but at 37jC, its ability to bind DNA and activate transcription is severely weakened or lost and acts like mutant p53 (20, 21) . Using the human null p53 lung cancer cell line H1299 and prostate cancer cell line PC-3, we stably transfected the human temperature-sensitive p53 mutant Ala 143 (Val-Ala) for use as our model in previous studies. With these cell lines, we previously reported that Fas-mediated apoptosis occurred only with the WT p53 phenotype at 32.5jC but not at the mutant p53 temperature (22) .
PRIMA-1 (p53 reactivation and induction of massive apoptosis) is a chemical compound originally identified as a selective mutant p53-dependent growth suppressor by screening a library of low-molecular-weight compounds. This small molecule (molecular weight: 185) restored sequence-specific DNA binding and functional p53 conformation to mutant p53 protein in vitro and in situ (23, 24) . Results from screening PRIMA-1 in the National Cancer Institute cell line database showed a significant preference for growth inhibition of tumor cell lines expressing mutant p53 compared with lines expressing WT p53 (25) . The mechanisms responsible for this preferential activity, its effect on premalignant cells, and the pathways of cell death are unknown.
In this study, we examined the toxicity of PRIMA-1 to human colon premalignant and malignant cells and lung cancer cells. We also investigated its mechanism of action in the intrinsic and extrinsic pathways of apoptosis, as well as its effects on cell cycle regulatory proteins and the MAPK pathways. (26, 27) . AA/C1 (WT p53) is a clonogenic, nontumorigenic adenoma cell line (28) . These premalignant lines grow in vitro but cannot grow in vivo or in soft agar. H1299/ts p53-143#6 is the stably transfected temperature-sensitive p53 mutant Ala 143 in null p53 H1299 lung cancer cells described in our previous study (22) . The human colon cancer cell lines DLD-1 (mutant p53/Ser 241 Phe), SW480 (mutant p53/Arg 273 His), LOVO (WT p53), HCT116 (WT p53), and lung cancer cell line H1299 (null p53) were obtained from American Type Culture Collection (Rockville, MD). The premalignant colon cell lines RG/C2, BR/C1, and AA/C1 were maintained with a 1:1 mixture of DMEM/F12 supplemented with 5% horse serum, 4 mmol/L L-glutamine, 100 Ag/mL penicillin/streptomycin, 20 mmol/L HEPES, 10 Ag/mL insulin, 0.5 Ag/mL hydrocortisone, 100 ng/mL cholera toxin, and 20 ng/mL epidermal growth factor (26) . DLD-1, SW480, LOVO, HCT116, and H1299 cells were maintained in RPMI 1640 supplemented with 10% FCS. 4V,6-Diamidino-2-Phenylindole Staining Cells were treated with various concentrations of PRIMA-1 for different periods of time. Cells were washed with PBS, fixed in 4% paraformaldehyde at room temperature for 1 hour, and stained with 50 Ag/mL of 4V,6-diamidino-2-phenylindole (DAPI) at 4jC for 2 hours. Percentage of apoptotic cells was scored in at least 400 cells in each sample by fluorescence microscopy. The microscopy reader was blinded to the actual groups. Western Blot Cell lysates were prepared in lysis buffer [20 mmol/L TrisÁCl (pH 7.6), 1 mmol/L EDTA (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100, 10 Ag/mL aprotinin, 5 mmol/L benzamidine, 50 Ag/mL leupeptin, 10 Ag/mL pepstatin A, and 1 mmol/L phenylmethylsulfonyl fluoride] for 15 minutes on ice and centrifuged at 10,000 Â g for 30 minutes. Equal amounts of lysates (40 Ag) were boiled in SDS sample buffer and loaded on SDS-PAGE. After transfer, immunoreactive products were detected by the ECL system (Amersham Pharmacia, Piscataway, NJ). Expression of a-tubulin was used as a control.
Materials and Methods

Results
PRIMA-1^Induced Apoptosis in Mutant p53 Premalignant and Malignant Colon Cancer Cells
To investigate the selective toxicity of PRIMA-1 to premalignant and malignant colon cells, we studied three premalignant human lines (RG/C2, BR/C1, and AA/C1) and four malignant human lines (DLD-1, SW 480, LOVO, and HCT 116). In comparison to the WT p53 cell lines (AA/ C1, LOVO, and HCT 116), a greater percentage of apoptotic cells were found in the mutant p53 lines (RG/C2, BR/C1, DLD-1, and SW480) after exposure to 100 Amol/L PRIMA-1 for 24 hours by DAPI staining (Fig. 1 ). In addition, Annexin V assays were done in human malignant DLD-1, SW480, LOVO, and HCT116 cell lines. As shown in Fig. 2 , PRIMA-1 induced significantly more apoptosis in Annexin V assays in the mutant p53 lines DLD-1 and SW480 cells than the WT p53 lines (LOVO, HCT116) after exposure to 100 Amol/L PRIMA-1 for 16 hours (average 68% versus 13%, respectively). The results showed that PRIMA-1 preferentially induced more cell death in the mutant p53 lines than in the WT p53 premalignant and malignant colon cells. Also, it showed for the first time that premalignant cells with mutant p53 were as sensitive to PRIMA-1 as malignant cells with mutant p53.
PRIMA-1^Induced Apoptosis in the TemperatureSensitive p53 Mutant 143 Model
To further substantiate whether PRIMA-1 was more toxic to mutant or WT p53 cancer cells for induction of apoptosis, we established stable transfectants of human temperature-sensitive p53 mutant 143 (Val-Ala) in the null p53 human lung adenocarcinoma cancer cell line H1299 (22) . Cells were preincubated at 37jC or 32.5jC for 16 hours and then treated with 50 or 100 Amol/L PRIMA-1 for 24 hours. Apoptotic cells were determined by DAPI staining and TdT (TdT-mediated nick end labeling, TUNEL) assays. The results are shown in Fig. 3 . PRIMA-1 was more toxic to H1299/ts p53-143#6 cells at the mutant p53 temperature (37jC) than at its WT p53 temperature (32.5jC). The degree of apoptosis was as follows: 58% at 37jC and 11% at 32.5jC by DAPI staining (Fig. 3A ) and 65% at 37jC and 20% at 32.5 jC by TdT assay (Fig. 3B ) after exposure to 100 Amol/L PRIMA-1. In addition, there was only 8% apoptosis in nontransfected null p53 H1299 cells exposed to 100 Amol/L PRIMA-1 at either temperature by both assays (Fig. 3A and B). These data indicated that PRIMA-1 was preferentially more toxic to cells expressing the mutant p53 form than WT p53 form in H1299 lung cancer cells and its induction of apoptosis was p53 dependent.
The Effect of PRIMA-1 on Cell Cycle To determine whether PRIMA-1 had an effect on the cell cycle, DNA content analyses for G 1 and G 2 peaks were done in temperature-sensitive p53 mutant H1299 stable transfectants. When cells were treated with 50 Amol/L PRIMA-1, the G 2 peak increased only at 37jC, but not at Fig. 4 .
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.5jC, at 6-and 12-hour time points as shown in Fig. 4 . The cell cycle distribution changes after treatment with 50 Amol/L PRIMA-1 for up to 48 hours is summarized in Table 1 . In addition, these results were also replicated with BrdUrd staining/fluorescence-activated cell sorting analysis (data not shown). The data suggested that PRIMA-1 preferentially caused G 2 arrest in the H1299 cells expressing the mutant p53 form at 37jC, but not at the WT p53 temperature.
The Effect of PRIMA-1 on p53 Target Genes Involved in Cell Cycle Control and Apoptosis
To investigate whether the G 2 arrest of PRIMA-1 on cell cycle was potentially related to cell cycle regulatory proteins directly transactivated by functional p53, we investigated the expression of p21, GADD45, and 14-3-3j in H1299/ts p53-143 lung cancer cells, DLD-1, and HCT116 colon cancer cells. As shown in Fig. 5A , expression of p21 and GADD45, but not 14-3-3j, was increased by PRIMA-1 exposure in a time course study in H1299/ts p53-143 cells with mutant p53 form at 37jC and the mutant p53 DLD-1 colon cancer cells. However, there was no change of expression of these proteins in the WT p53 HCT116 cells Fig. 5A ). These data suggested that PRIMA-1 induced G 2 arrest and it was preceded or occurred concomitantly with increased levels of p21 and GADD45. Levels of Bax, Bcl-XL, and FAS were examined from the above experimental groups to investigate the involvement of the intrinsic and extrinsic pathways in the mechanism of apoptosis, respectively. As shown in Fig. 5B , the H1299 stably transfected temperaturesensitive p53 line showed no change in the levels of these proteins. The same findings were also detected in the DLD-1 and HCT116 cell lines (data not shown), implying that the intrinsic and extrinsic pathways of apoptosis were not involved in the mechanism of cell death by PRIMA-1 in these different cell lines.
The Effect of MAPK Inhibitors on PRIMA-1^Mediated Apoptosis
To investigate other possible mechanisms of PRIMA-1 -induced apoptosis in mutant p53 cells, MAPK inhibitors were used to determine whether segments of the MAPK pathway were involved. Fig. 6A showed the results of the effect of three inhibitors on PRIMA-1 -mediated apoptosis by propidium iodide staining. The JNK inhibitor SP 600125 at 50 Amol/L reduced the increase in apoptosis from 3.6-fold to 1.4-fold in the mutant p53 colon cancer cell line DLD-1 after exposure to 100 Amol/L PRIMA for 24 hours. Similar results were also obtained in the premalignant RG/C2 mutant p53 cells by DAPI staining as shown in Fig. 6B . In addition, similar results were detected in a time course study of 50 Amol/L JNK inhibitor SP 600125 in H1299/ts p53-143 cells at 37jC with DAPI staining as shown in Fig. 6C . However, the p38 MAPK inhibitor SB 203580 and the ERK inhibitor PD 98059 at 50 Amol/L did not significantly inhibit PRIMA-1 -induced cell death (Fig 6A) . All three MAPK inhibitors at 50 Amol/L did not show significant toxicity in control experiments without PRIMA-1 in the DLD-1, RG/C2, and H1299/ts p53-143 cell lines (Fig. 6A-C) . These results indicated that the JNK pathway played an important role in PRIMA-1 -induced apoptosis in the three different cell lines with mutant p53.
Expression of DN-JNK and Its Effect on PRIMA-1Î nduced Cell Death
To further show that the JNK pathway was essential to the mechanism of cell death induced by PRIMA-1, we modulated JNK expression via an Ad5 adenovirus system. DLD-1 cells were transiently transfected with adenovirus containing either control Ad-vector, Ad-WT-JNK, or Ad-DN-JNK with three different multiplicities of infection (MOI) for 36 hours. The expression of WT-JNK and DN-JNK was detected by Western blot as shown in Fig. 7A . Approximately equal amounts of WT-JNK and DN-JNK were expressed from transfection of 50 or 100 MOI adenovirus in a dose-dependent manner. Cells were treated with 50 or 100 Amol/L PRIMA-1 for an additional 24 hours after being transfected with 50 MOI adenovirus of either Ad-vector, Ad-WT-JNK, or Ad-DN-JNK for 36 hours. The TdT assay was done for detection of apoptosis. DN-JNK expression decreased induction of apoptosis by 100 Amol/L PRIMA-1 from 28% to 11% in DLD-1 cells (Fig. 7B) . In experiments with H1299/ts p53-143#6 cells treated with 50 Amol/L PRIMA-1, DN-JNK expression reduced apoptosis from 21% to 10% (Fig. 7C) . However, transfection with Ad-WT-JNK did not produce a significant reduction in apoptosis in these cells (Fig. 7B and C) . These results with JNK chemical inhibitor and DN-JNK showed that the JNK MAPK pathway played a critical role for PRIMA-1 -induced apoptosis in these human premalignant and malignant cell lines.
Discussion
The low-molecular-weight compound PRIMA-1 was identified in a cellular screen of a chemical library from the National Cancer Institute using Saos-2-His 273 osteosarcoma cell line that expresses tetracycline-regulated mutant p53 (23). Li et al. (24) and Baker et al. (25) had reported that PRIMA-1 restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in situ. PRIMA-1 induced apoptosis in a mutant p53 -dependent manner using a panel of cell lines with expression of most common p53 mutant proteins. In this study, we showed, for the first time, that PRIMA-1 was not only toxic to malignant mutant p53 cells but was also toxic to premalignant mutant p53 human colon cells using DAPI and Annexin V assays (Figs. 1 and 2 ). In addition, PRIMA-1 was significantly more toxic to the mutant p53 conformation than the WT p53 form in lung cancer H1299 cells stably transfected with a human temperature-sensitive p53 mutant Ala 143 (Fig. 3) . We have also found the selective induction of apoptosis by PRIMA-1 in mutant p53 human cancer cells from breast, mesothelioma, and pancreatic cell lines compared with WT p53 lines. 4 PRIMA-1 induced G 2 arrest in H1299 cells expressing human temperature-sensitive p53 mutant Ala 143 at 37jC but not at 32.5jC ( Fig. 4; Table 1 ). This was associated temporally with an induction of p21 and GADD45 in these cells, as well as in the mutant p53 DLD-1 cells, which is likely responsible for the PRIMA-1 -induced G 2 arrest. However, p21 and GADD45 were not induced in the HCT116 cells with WT p53 (Fig. 5A) . Induction of p21 by PRIMA-1 has been observed in human lung cancer cell line H1299 expressing mutant p53 His 175 , as well as in the human colon mutant p53 cancer cell line SW 480 (23) . Induction of p21 mainly occurs in p53-dependent and p53-independent G 1 arrest and apoptosis (29 -32) . p21 also participates in the G 2 checkpoint, as shown in altered HCT116 colon cancer cells lacking either p21 or p53, which did not arrest in G 2 after exposure to ionizing radiation (33) . Cisplatin and BBR3464, a trinuclear platinum complex that exhibits potent cytotoxicity and efficacy against cisplatin-resistant tumors, induced p21 expression and caused a selective G 2 -M arrest in ovarian cancer cells (34) . T-cadherin -mediated cell growth regulation involves G 2 , but not G 1 , phase arrest and requires p21 expression (35) .
These observations suggested a novel mechanism of growth regulation for drugs, inducing p21 expression and subsequent G 2 arrest. Our results support the concept that p21 induction by PRIMA-1 in mutant p53 cells can mediate a p53-dependent G 2 arrest mechanism. GADD45 is another transcriptional target of p53 implicated in regulating the G 2 -M transition, but whether GADD45 plays a direct role in apoptosis remains unclear (12) . GADD genes are stress response genes and classified as GADD34, GADD45, and GADD153, and they are induced by stressors, such as UV irradiation, chemical carcinogens, and starvation, respectively (36, 37) . The GADD family of genes, by means of the p38 MAPK pathway, has been shown to play an important role in melanoma differentiation-associated gene-7 (mda-7) -induced apoptosis in human melanoma cells (38) . Peroxynitrite-mediated oxidative stress activated p38 MAPK to induce three GADD genes in human neuroblastoma SH-SY5Y cells (39) . We found the induction of GADD45 by PRIMA-1 in cell lines with only mutant p53 including the human lung cancer H1299 temperaturesensitive p53 mutant Ala 143 cells and human colon cancer DLD-1 cells, but not in the HCT116 line with WT p53 (Fig.  5A) . The p38 MAPK inhibitor SB 203580 did not block PRIMA-1 -induced apoptosis in DLD-1 cells (Fig. 6A) , suggesting that the GADD45 gene was involved in the G 2 arrest of the cell cycle in PRIMA-1, but the p38 MAPK pathway may not be required for PRIMA-1 to induce cell death in these colon cancer cells. Induction of apoptosis by PRIMA-1 was potently inhibited in DLD-1, RG/C2, H1299/ p53-143#6 cell lines by specific JNK inhibitor SP 600125 and DN-JNK (Figs. 6 and 7B, C) . Generally, activation of ERK forms of MAPK elicits survival responses, whereas activation of the stress-activated protein kinases, JNK, and p38 generally promote cell death (40, 41) . The effects of these MAPKs seem to be cell type specific. Paclitaxel-induced apoptosis in MCF-7 cells (WT p53) can be inhibited in a p53-dependent manner by the JNK inhibitor SP 600125 (42) and can also be blocked with inhibitors of the ERK and p38 MAPK pathways in a p53-independent manner (43) . Cantharidin-induced apoptosis via activation of p38 MAPK and JNK pathways were associated with mutant p53 and activation of caspase-3 (44) . These data suggest that agentinduced G 2 arrest and apoptosis can be through p53-dependent and p53-independent MAPK pathways in a cell type -specific manner.
Specific caspase-8, caspase-9, and caspase-3 inhibitors, each at 4 Amol/L, either alone or all together did not block PRIMA-1 -induced cell death under the conditions in our study in the lung cancer cell line H1299 temperature-sensitive p53-143 and colon cancer cell line DLD-1 (data not shown). However, the pan-caspase inhibitor VAD-FMK, at 100 Amol/L, completely blocked PRIMA-1 -mediated cell death in human non -small cell lung carcinoma cell lines H460 and H23 (45) . It is possible that the extraordinarily high concentration of the pan-caspase inhibitor (100 Amol/L) in this previous study may have been nonselective. In our experiments, the pancaspase inhibitor VAD-FMK at 40 Amol/L also reduced PRIMA-1 -induced cell death by 40% in mutant p53 colon cancer DLD-1 cells. Thus, PRIMA-1 did not induce any activities of the caspases tested (caspase-8, caspase-9, or caspase-3), but high concentrations of the pan-caspase inhibitor VAD-FMK reduced apoptosis induced by PRIMA-1, suggesting either a nonspecific toxic effect or an unknown caspase may be involved in this mechanism. Collectively, these results and prior studies suggest that PRIMA-1 -induced apoptosis can be through a caspasedependent or caspase-independent pathway possibly dependent upon cell line type.
Tumors carrying mutant p53 are often more resistant to conventional cancer therapy (9, 46, 47) . Therefore, it is important to develop novel therapeutic strategies that target mutant p53 in tumors. A number of small molecules, such as CP-31398, WR1065, and PRIMA-1, have been identified, which restore partial degree of native conformation and WT function to mutant p53 (48) . The study of the structure-activity relationship of these molecules could be helpful in the future for the discovery of more potent analogues for restoration of p53 function in mutant p53 tumors.
In conclusion, PRIMA-1 selectively induced apoptosis only in mutant p53, but not in WT p53, premalignant colon cells, and in malignant colon cells. It also induced significantly more apoptosis in human lung cancer H1299 cells with mutant p53 conformation than the WT p53 conformation. Induction of G 2 arrest by PRIMA-1 is probably conferred by up-regulation of p21 and GADD45. Induction of apoptosis occurred through the JNK pathway but did not require the p38 MAPK or ERK pathways as shown in the dominant-negative and pharmacologic inhibitor experiments. There was no evidence for involvement of Fas, the Bcl-2 family proteins, and caspase-8, caspase-9, and caspase-3 in PRIMA-1 -induced apoptosis in premalignant and malignant colon cells and malignant lung cells with mutant p53. Our new findings suggest that PRIMA-1 -induced cell death is through the JNK pathway in a p53-dependent manner and this may have important implications for cancer treatment, especially for colon cancer in different phases of transformation, including premalignant and malignant states. This work shows the selective efficacy of PRIMA-1 for inducing apoptosis in premalignant mutant p53 colon cells, which could possibly eliminate cells in evolution to frank malignancy. There are currently very few therapeutics or clinical modalities outside of surgery that have this potential. PRIMA-1 may serve as a leading prototypic compound for the development of new p53-targeting agents for more potent small molecules that work at clinically achievable concentrations.
